H.R. 2351, a bill to direct the Commandant of the Coast Guard to update the policy of the Coast Guard regarding the use of medication to treat drug overdose, and for other purposes
Cost Estimate
As ordered reported by the House Committee on Transportation and Infrastructure on April 2, 2025
H.R. 2351, a bill to direct the Commandant of the Coast Guard to update the policy of the Coast Guard regarding the use of medication to treat drug overdose, and for other purposes
As ordered reported by the House Committee on Transportation and Infrastructure on April 2, 2025
By Fiscal Year, Millions of Dollars
2025
2025-2030
2025-2035
Direct Spending (Outlays)
0
0
0
Revenues
0
0
0
Increase or Decrease (-) in the Deficit
0
0
0
Spending Subject to Appropriation (Outlays)
*
1
not estimated
Increases net direct spending in any of the four consecutive 10-year periods beginning in 2036?
No
Statutory pay-as-you-go procedures apply?
No
Mandate Effects
Increases on-budget deficits in any of the four consecutive 10-year periods beginning in 2036?
H.R. 2351 would direct the Coast Guard (USCG) to carry naloxone and similar overdose medications at all of its facilities, implement a system to track their distribution, and report on those efforts to the Congress. The bill also would codify existing policies prohibiting the manufacture or distribution of controlled substances aboard vessels.
Under current law, the USCG is not required to carry naloxone; however, all designated law enforcement units are currently equipped with it. Using information from the Coast Guard, CBO estimates that it would cost less than $500,000 over the 2025-2030 period for the agency to supply naloxone to additional facilities. CBO estimates that maintaining the tracking system and other reporting requirements would cost less than $500,000 over the 2025-2030 period. In total, CBO estimates that implementing H.R. 2351 would cost $1 million over the 2025-2030 period. Any related spending would be subject to the availability of appropriated funds.
The CBO staff contacts for this estimate are Kelly Durand and Aaron Krupkin. The estimate was reviewed by H. Samuel Papenfuss, Deputy Director of Budget Analysis.
